CareLit · DOI-Nachweis · Klinische Pädiatrie
Phase 1/2 Study of Brentuximab Vedotin in Pediatric Pts with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 HL Data
DOI 10.1055/s-0034-1371149
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Locatelli, K Neville, A Rosolen, J Landman-Parker, N Aladjidi, A Beishuizen, S Daw, L Gore, ARK Franklin, A Fasanmade, J Wang, J Sachs, C Mauz-Körholz
ZeitschriftKlinische Pädiatrie
Ausgabe03/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Question: To evaluate the safety and efficacy of brentuximab vedotin, a CD30-targeted antibody-drug conjugate, in pediatric pts with R/R HL or sALCL (currently approved in the USA and EU for use in adults with R/R HL or sALCL). We report initial phase 2 response, safety and pharmacokinetics (PK) data in R/R HL pts at the RP2D of 1.8 mg/kg Q3wk. Methods: This ongoing phase 1/2 prospective, open-label, multicenter stu…
Zitieren
Zitierempfehlung
F Locatelli, K Neville, A Rosolen, J Landman-Parker, N Aladjidi, A Beishuizen, S Daw, L Gore, ARK Franklin, A Fasanmade, J Wang, J Sachs, C Mauz-Körholz (2014) Phase 1/2 Study of Brentuximab Vedotin in Pediatric Pts with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 HL Data. Klinische Pädiatrie (03). https://doi.org/10.1055/s-0034-1371149
Mit CareLit weiterarbeiten